Is Stem Cell Therapy FDA-Approved? What Patients Need to Know in 2026

The single most-asked question about regenerative medicine, after "how much does it cost," is "is it FDA-approved." The honest answer is nuanced, and most clinics handle the nuance badly, either by overclaiming approval or by handwaving the regulatory framework entirely.

This guide walks through the actual FDA regulatory picture for stem cell therapy, exosomes, PRP, and related products in 2026. It explains what approval and clearance actually mean, what the 361 vs 351 pathways are, what enforcement looks like, and how patients can verify a clinic's compliance. The goal is to give you enough framework to evaluate any clinic's regulatory claims accurately.

This is the area where the marketing pitch and the regulatory reality most often diverge. Knowing the difference protects you.

The headline answer

No orthopedic stem cell injection has FDA drug approval as of 2026. There is no FDA-approved drug or biologic product specifically for intra-articular stem cell therapy in joint osteoarthritis, tendinopathy, or any other common orthopedic indication.

The cell products used in legitimate clinical practice operate under a different regulatory framework: 21 CFR 1271, which governs Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps). That framework is real, the compliance requirements are real, but it's not the same as drug approval.

When a clinic says their stem cells are "FDA approved," they are almost always overstating the regulatory status. What's accurate is something like: "Our cell product is sourced from an FDA-registered tissue establishment under 361 HCT/P regulations, with documented donor screening, sterility testing, and characterization."

The distinction matters. Read on.

The two regulatory pathways: 361 vs 351

The FDA divides HCT/Ps into two pathways based on how the cells are processed and how they're used:

Section 361 HCT/Ps

These are cells and tissues that meet four criteria:

1. Minimally manipulated. The processing doesn't fundamentally change the cell's biological characteristics.
2. Intended for homologous use. The cells are used to perform the same basic function in the recipient as they did in the donor.
3. Not combined with another article, with limited exceptions.
4. Either don't depend on the metabolic activity of the cells for primary function, or are used in autologous use, or in first/second-degree relatives.

Products meeting all four criteria can be marketed without pre-market FDA approval. They do require:

• Tissue establishment registration with the FDA
• Donor eligibility determination (infectious disease screening, risk-factor assessment)
• Compliance with Good Tissue Practice (GTP)
• Adverse event reporting

Allogeneic umbilical-derived MSCs from screened donors, used to support repair in tissues with similar biological function, can fall under 361 when handled correctly. This is the pathway most reputable allogeneic regenerative products operate under.

Section 351 HCT/Ps

These are products that don't meet all four 361 criteria. They're regulated as drugs and biologics. They require:

• Pre-clinical safety studies
• An Investigational New Drug (IND) application
• Phase 1, 2, and 3 clinical trials
• Biologics License Application (BLA) approval

The 351 pathway is what FDA approval normally means. It's expensive, time-consuming, and rigorous. Very few cellular products have completed 351 approval for orthopedic indications.

Where the line gets blurry

The 361 vs 351 line has been the subject of ongoing FDA guidance, enforcement, and litigation. Specific gray zones:

Enzymatically digested adipose tissue (SVF). The FDA has consistently treated enzymatic digestion of adipose tissue as more-than-minimal manipulation, pushing SVF preparations into the 351 pathway. Many clinics offering SVF are not 351-registered.

Culture-expanded MSCs. Cells that are expanded in culture (grown to higher numbers in a lab) are generally considered more-than-minimally manipulated and fall into 351.

Non-homologous use. Using cells for purposes other than their normal biological function (for example, using skin-derived cells to treat joint disease) typically pushes into 351.

Combination products. Cells combined with scaffolds, devices, or significant adjuncts may shift into 351 or even into combination product regulation.

When a clinic claims their product operates under 361, the legitimacy of that claim depends on whether the processing actually meets the 361 criteria. Some clinics misclassify products they should be operating under 351.

What's actually been FDA-approved

Concretely, here's what has formal FDA approval as of 2026 in adjacent spaces:

Hematopoietic stem cell transplant products. Various bone marrow and cord blood products for specific cancer indications. Long-established, fully approved through the BLA pathway.

Esketamine (Spravato). FDA-approved nasal spray for treatment-resistant depression and acute suicidal ideation in MDD. The IV ketamine used at most ketamine clinics is the racemic compound, used off-label, not the FDA-approved formulation.

Several MACI (matrix-induced autologous chondrocyte implantation) and other cellular cartilage repair products. Approved for specific cartilage defect indications, used in surgical settings.

Various PRP and BMAC processing devices. Some FDA-cleared as medical devices (510(k) pathway). This is different from approval of the cell product or PRP itself.

Specific gene therapies. Several CAR-T therapies and gene therapy products for cancer and rare disease indications.

What is not FDA-approved in 2026:

• Intra-articular allogeneic MSC injection for knee osteoarthritis
• Intra-articular MSC or exosome therapy for any joint
• Intravenous MSC infusion for orthopedic, autoimmune, or wellness indications (outside of approved trials)
• Intra-disc cellular therapy
• Adipose-derived stem cell therapy for orthopedic indications

If a clinic claims any of these are "FDA approved," they are overstating the regulatory status. The accurate language is to describe the 361 HCT/P pathway and the processor's tissue establishment registration.

FDA enforcement history

The FDA has taken enforcement action against clinics marketing unapproved cellular products. A few notable patterns:

Warning letters. The FDA has issued dozens of warning letters to stem cell clinics in the last decade, primarily for marketing claims that exceed regulatory authorization, for using products that should be operating under 351 without approval, and for failures of basic compliance with 1271 requirements.

Injunctions. The FDA has pursued and obtained court injunctions against several clinic networks, requiring them to stop offering specific products or making specific claims.

The US Stem Cell ruling. In 2019, a federal court ruled in favor of the FDA in a case against US Stem Cell, finding that the company's SVF product was a more-than-minimally manipulated cellular product requiring 351 approval. The ruling was significant because it clarified the FDA's authority over adipose-derived cellular products and set precedent for subsequent enforcement.

The Cell Surgical Network case. Another federal court action targeting a clinic network operating under similar regulatory positioning.

Periodic FDA public statements. The FDA's Patient and Consumer Information page on regenerative medicine warns explicitly about unapproved products being marketed as therapies.

The enforcement history matters because it tells you the regulatory landscape isn't just paper. Clinics that operate outside the 361 framework do face real consequences. Patients who use those products bear real safety and efficacy risk.

How to verify a clinic's compliance

A practical checklist:

Ask which regulatory pathway the product is in. A credible answer specifies 361 HCT/P and names the processor. A non-answer or a vague "FDA approved" claim is a problem.

Ask for the processor's name. Reputable cell processors are public companies or established tissue establishments with verifiable presence.

Verify the processor's FDA registration. The FDA maintains a public Tissue Establishment Registration database. You can search by processor name to confirm registration and view the establishment's history. The database is at https://www.accessdata.fda.gov/scripts/cber/CFAppsPub/tiss/index.cfm.

Ask for the lot certificate of analysis. Every reputable cell product comes with a lot-specific document showing donor screening results, sterility testing, cell count, viability percentage, and any other characterization data. Real clinics can show you this. Fake clinics can't.

Ask if the processor or clinic has received any FDA warning letters. A clean answer to this question is reassuring; a fudged answer is a flag.

Check the FDA's warning letter database. Searchable at https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters. Search for the clinic name or the processor name.

Look at the clinic's consent forms. Real consent documents describe the regulatory category accurately and don't claim FDA approval where there isn't any.

Specific marketing language to watch out for

The pattern of regulatory misrepresentation is consistent. Common phrases that mean less than they sound:

"FDA approved." As discussed, almost no orthopedic stem cell product is. Phrase used by clinics misrepresenting the actual status.

"FDA cleared." Some PRP and processing devices are cleared as medical devices. The clearance applies to the device, not to the cell product or to a specific clinical claim.

"FDA registered." Tissue establishments register with the FDA. Registration doesn't constitute approval; it's a compliance step. The phrase is sometimes used to imply more than it does.

"FDA compliant." Vague. May or may not mean anything specific. Ask what specifically is compliant with what.

"FDA-approved facility." Facilities don't get FDA approval. They get registered or inspected. Cell products operate under regulatory pathways; the facility itself isn't "FDA-approved."

"Made in an FDA-approved lab." Same issue. Labs aren't FDA-approved. They're registered tissue establishments or 351 manufacturers.

"Used in over 1 million procedures with no side effects." Volume claims that aren't independently verifiable. The track record of real allogeneic MSC products in published cohorts is good, but specific marketing claims should be substantiated by something more than the clinic's own count.

If a clinic uses any of these phrases prominently in their marketing without specifying what's actually true, treat that as a sign to dig deeper.

The exosome regulatory question

Exosomes occupy their own regulatory zone, currently more ambiguous than cellular products.

The FDA has issued public statements expressing concern about exosome products marketed for orthopedic, neurologic, and systemic indications. The agency has sent warning letters to clinics making unapproved drug claims for exosome products.

At the same time, exosome products from reputable cell processors, sold as cell-free biologic preparations, exist in a category that hasn't been fully resolved by FDA guidance. Some operate under principles analogous to 361 HCT/P; others would more clearly fall under 351 if pushed.

What this means for patients:

The regulatory ambiguity itself is a flag. Be more skeptical of exosome-only protocols than of well-characterized cellular protocols.

Ask the same verification questions as for cellular products: source, processor, lot documentation, regulatory pathway claim.

Be especially skeptical of "wellness" or "anti-aging" exosome IV protocols, which the FDA has specifically cited as concerning.

We use exosomes alongside cellular protocols, sourced from reputable FDA-registered processors. We don't offer standalone exosome wellness drips.

What the FDA's role does and doesn't cover

A common patient misunderstanding: assuming FDA oversight is comprehensive in this space. It isn't.

The FDA regulates:

• The cell product itself (sourcing, processing, donor screening)
• The processor (tissue establishment registration)
• Marketing claims that constitute drug claims
• Specific products that fall into 351 territory

The FDA does not regulate:

• The clinical practice of medicine (that's a state board function)
• The price clinics charge
• Whether the procedure was clinically appropriate for the patient
• The skill of the operator
• Whether the patient was given adequate informed consent

State medical boards regulate physician licensure, the practice of medicine, and adjacent issues. The Texas Medical Board, for example, would handle complaints about a physician's practice, including failure to obtain informed consent or practicing outside the scope of training. The FDA wouldn't.

This split means that even a clinic with technically compliant cell products can be a bad clinic from a clinical practice standpoint, and vice versa. Verifying FDA compliance is necessary but not sufficient.

International "stem cell tourism"

A few patients consider traveling abroad for stem cell therapy. The FDA does not regulate medical care in foreign countries. The regulatory frameworks vary widely:

Mexico, parts of the Caribbean, and parts of Asia have more permissive regulatory environments for cellular therapies. Some clinics in these regions offer protocols that wouldn't pass US 361 standards, including products with less rigorous donor screening, less complete characterization, or applications that go well beyond what US clinics can legally market.

Some of these clinics deliver competent care. Many don't. Without the FDA framework, the patient bears more of the safety verification burden, and recourse if something goes wrong is limited.

The cost savings of medical tourism for stem cell therapy are often less than they appear once travel, accommodations, and follow-up are included. The risk profile is materially different from US-based care.

We don't recommend stem cell tourism in 2026. The US regulatory environment, for all its limitations, provides a baseline of safety verification that's worth the price premium for most patients.

What good regulatory compliance looks like at a clinic

If you walk into a clinic and ask the regulatory questions, the answers should sound roughly like this:

"Our cell product is allogeneic, umbilical-derived MSCs from [Processor Name], an FDA-registered tissue establishment under 21 CFR 1271. The product operates under the 361 HCT/P pathway, meeting the criteria for minimal manipulation and homologous use in joint and soft tissue applications. Each lot ships with a certificate of analysis documenting donor screening, sterility testing, cell count, and viability. We can show you a sample lot certificate. The processor maintains FDA registration which you can verify at the FDA's tissue establishment database."

If the answer sounds like that or close to it, you're talking to a clinic that takes regulatory compliance seriously. If the answer is vague, evasive, or claims FDA approval that doesn't exist, walk away.

What the future might hold

A few directions the regulatory landscape may move in the coming years:

Specific 351 approvals for certain cellular products. Several companies have ongoing clinical trials seeking BLA approval for specific MSC products in specific indications. If any of these complete approval, the landscape changes; specific FDA-approved cellular therapies become possible.

FDA guidance clarifications. The 361 vs 351 boundary will probably get further refined through guidance and enforcement actions over the next several years.

Coverage and reimbursement expansion. If approval happens, CMS and commercial insurance coverage may follow for specific indications.

Continued enforcement against non-compliant clinics. The FDA's enforcement posture has been relatively consistent. Expect continued attention to clinics making drug-like claims for unapproved products.

For now, in 2026, the framework is what it is. Patients can get high-quality, regulatory-compliant care from credible clinics. They can also be sold non-compliant products by clinics that misrepresent the regulatory status. The questions in this guide help you tell which is which.

What this means for you, practically

A short summary of the practical implications:

If a clinic uses the phrase "FDA-approved stem cells" for orthopedic care, they're either misinformed or being misleading. Verify before paying.

Use cell products from FDA-registered tissue establishments. Verify the registration.

Get lot documentation for any cellular procedure you receive.

Be especially careful around adipose-derived (SVF), culture-expanded, or "compounded" cellular products, all of which have higher regulatory risk profiles.

Avoid wellness-tier IV stem cell or exosome drips for healthy patients without a documented medical indication.

Avoid international stem cell tourism unless the foreign clinic meets standards equivalent to FDA 361 compliance, which is hard to verify.

Choose clinics that can answer the regulatory questions cleanly and in writing.

How to verify Apex's specific compliance

At Apex, we use allogeneic, umbilical-derived MSCs from FDA-registered tissue establishments. We use MSC-derived exosomes from FDA-registered processors. We can show you the lot certificate of analysis for any cellular product used in your procedure. We document the regulatory pathway, the processor, and the product specifics in your chart.

For verification:

The Texas Medical Board confirms our physician's licensure: search at tmb.state.tx.us.

The NPI registry confirms practice identifiers: search 1124445259 at npiregistry.cms.hhs.gov.

The FDA tissue establishment database lets you verify processor registration: https://www.accessdata.fda.gov/scripts/cber/CFAppsPub/tiss/index.cfm. We're happy to tell you the specific processors we use during the consultation so you can verify.

How to book

To discuss treatment, regulatory questions, or to get our specific processor information, call (972) 768-2328 or request a consultation at /#consult. We're at 2111 Kirkwood Blvd, Suite 110b, Southlake, TX 76092.

A short note from Dr. Abdullah

The regulatory environment in this space is one of the most important things patients should understand and one of the least well-explained by most clinics. The reason is uncomfortable: many clinics' marketing depends on a vague impression of regulatory legitimacy that doesn't survive close inspection. The good news is that you don't need a regulatory background to ask the right questions. The questions in this guide are sufficient to separate compliant clinics from non-compliant ones. Use them. The answer protects your safety, your money, and your outcome.